NMN / NAD+ precursor

Nicotinamide mononucleotide (NMN) is a small, naturally occurring molecule built from a nicotinamide (vitamin B3) base, a ribose sugar, and a phosphate group. It is one step away from NAD+ (nicotinamide adenine dinucleotide), a coenzyme that every cell uses for energy metabolism, DNA repair, and signaling. It is technically a nucleotide rather than a peptide, but it is grouped in longevity/"cell energy" ingredient libraries because it is a direct dietary precursor used to raise the body's NAD+ pool. It is found in trace amounts in foods like broccoli, avocado, edamame, and cucumber, and is sold as an oral dietary supplement.

Education only. This page summarises published research on a cosmetic or dietary ingredient. It is not medical advice and makes no treatment claims; for a finished product, follow its label.

Also known as: Nicotinamide mononucleotide, β-NMN, Beta-nicotinamide mononucleotide, NAD+ precursor, NAD booster
Class: NAD+ precursor / NAD+ biosynthesis intermediate (nucleotide, not a true peptide). Vitamin-B3 family / niacin-equivalent metabolite.

How does NMN and NAD+ work?

NAD+ levels decline with age, and many longevity-relevant enzymes (such as sirtuins and PARPs) consume NAD+ to do their work. NMN feeds the "salvage pathway" of NAD+ biosynthesis: in cells, the enzyme NMNAT converts NMN directly into NAD+, while NAMPT is the rate-limiting enzyme that makes NMN from nicotinamide upstream. Restoring NAD+ supports the NAD+/NADH redox cycling that powers glycolysis, the TCA cycle, and ATP production, and it provides substrate for sirtuin- and PARP-mediated processes. Notably, in humans orally dosed NMN is often not reliably detectable in plasma as intact NMN; it appears to be rapidly converted (partly via gut microbiota and salvage enzymes to nicotinamide and nicotinic acid mononucleotide) before being assembled into NAD+, so the measured readout is a rise in whole-blood NAD+ rather than circulating NMN.

What has NMN and NAD+ been studied for?

Raising blood/whole-blood NAD+ levels (the most consistent and best-supported effect)
Physical performance and aerobic endurance in older/middle-aged adults (e.g. six-minute walk distance)
Muscle strength and function in older adults
General healthy-aging / 'biological age' and quality-of-life measures
Glucose and lipid metabolism / insulin sensitivity (mixed, mostly non-significant results)
Fatigue and general energy / vitality

What does the evidence show?

Evidence is early and mixed. The single most reproducible finding across randomized controlled trials is that oral NMN raises blood NAD+ levels in a dose-related way and is well tolerated. Some RCTs report modest improvements in physical performance (six-minute walk distance, endurance) and self-reported quality of life, with several pointing to ~600 mg/day as a plateau for NAD+ and performance effects. However, systematic reviews (e.g. a review of ~10 RCTs, ~437 participants, mean follow-up ~9.6 weeks) found that most clinically relevant outcomes were NOT significantly different from placebo despite the NAD+ rise, and results for insulin sensitivity and metabolic endpoints are inconsistent. Key caveats: studies are short (typically 6-12 weeks) and small, populations are mostly healthy middle-aged/older adults, long-term outcomes are unstudied, much of the foundational anti-aging data is from rodents (which may not translate), individual variability (genetics, microbiome, lifestyle) is large, and some industry sponsorship and publication-bias concerns exist. The dramatic mouse "anti-aging" results have not been matched by human disease- or lifespan-outcome data.

What is known about the safety of NMN and NAD+?

Across human trials, oral NMN has been well tolerated with no serious adverse events reported at single doses and at chronic daily dosing up to about 900 mg/day for periods generally up to 12 weeks (a separate short, 4-week safety study tested 1250 mg/day without serious adverse events). Reported side effects are typically mild and infrequent (e.g. occasional nausea, flushing, headache, fatigue, diarrhea, indigestion). Long-term (multi-year) safety is not established, and there is theoretical discussion in the literature about whether sustained NAD+/precursor elevation could influence cell proliferation pathways, so caution is reasonable for people with active or prior cancer. Not studied for safety in pregnancy or breastfeeding, or in children. People who are pregnant, breastfeeding, have a medical condition, or take medications should consult an independent qualified professional before use. Supplement quality varies between brands (purity, actual content, contaminants), which is itself a safety consideration.

What is the legal status of NMN and NAD+?

In the United States, NMN's status changed over time. In late 2022 the FDA took the position that NMN was excluded from the dietary-supplement definition because it had been authorized for investigation as a new drug (an Investigational New Drug application predated its marketing as a supplement). Following citizen petitions and legal action by industry groups, on September 29, 2025 the FDA reversed course and confirmed that beta-nicotinamide mononucleotide (NMN) is lawful for use in dietary supplements (acknowledging it was sold as a supplement as early as 2017), and in early December 2025 issued letters to ingredient suppliers setting aside its prior exclusion determinations and clarifying that NMN is no longer excluded from the dietary-supplement definition. So as of 2026 NMN may be lawfully marketed as a dietary supplement in the US (it is a supplement, not an FDA-approved drug, and carries no approved treatment claims). It is not a controlled substance and is not on the WADA prohibited list. Status differs by country (for example it has faced restrictions or non-novel-food positions in some other markets), so regional rules apply.

What is the half-life of NMN and NAD+?

A precise human plasma half-life is not well established. NMN is orally bioavailable but is absorbed and converted very rapidly: in several human studies intact NMN was difficult or impossible to reliably detect in plasma, while downstream NAD+ (and nicotinic acid mononucleotide) rose, indicating fast conversion via salvage enzymes and gut microbiota. In rodents, oral NMN appears in tissues within minutes and is incorporated into NAD+ within roughly 15-30 minutes; the functionally relevant readout in humans is the slower rise and decay of the whole-blood NAD+ pool over hours to days rather than a measurable circulating NMN half-life.

Sources

From the Peppies Peptide Intelligence Library: an educational summary of the published literature, not medical advice. No dosing, preparation or administration instructions are given on these pages. Last updated 2026-09-24. Corrections: support@peppies.eu.